Kilitch Drugs (India) Limited share price

Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, anticoagulant, narcotic, oncology, ophthalmic, antifungal, corticosteroid, anticoagulant, and other applications, as well as vaccines, veterinary product…Read more

Website NSE हिंदी में BSE

HealthcareDrug Manufacturers - Specialty & GenericNSE: KILITCHISIN INE729D01010

16 Oct 2026, 3:29 PM IST₹230.40▼ 5.80 (2.46%)

Market Cap₹ 806 Cr.
Current Price₹ 230.40
High / Low₹ 268 / 117
Stock P/E26.2
Book Value₹ 80
Dividend Yield0.00 %
ROCE13.2 %
ROE12.50 %
Face Value₹ 10.0

More figures (10)

EPS (TTM)₹ 8.81
Price / Book2.88
OPM14.5 %
Debt / Equity0.32
Sales growth (5Y)28.0 %
Profit growth (5Y)50.9 %
Promoter holding71.8 %
EV / EBITDA22.6
Beta0.31
All-time high₹ 268

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
KILITCH	+22.02%	+26.07%	+77.14%	+31.58%	+23.74%	+21.39%	+23.07%
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

Kilitch Drugs (India) Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹806 crore.
It trades at 26.2 times its last 12 months' earnings and 2.9 times book value.
Revenue grew 28.0% a year over the last 5 years, profit 50.9% a year.
Return on equity was 12.5% and return on capital employed 13.2% in the latest year.
Debt was 0.32 times shareholders' equity.
The share price is 14.0% below its 52-week high and up 23.7% over one year.
Promoters and insiders hold about 71.8%; institutions about 0.0%.

Pros

Sales have grown 28.0% a year over the last 5 years.
Profit has grown 50.9% a year over the last 5 years.
Borrowings are moderate at 0.32 times shareholders' equity.

Cons

Latest quarter (Jun 2026): profit fell 13% from a year ago.
Promoter holding has fallen by 5.46 points over 3 years, to 63.77%.
The company has not paid a dividend recently.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Kilitch Drugs (India) Limited

Employees: 236
Head office: Mumbai

HealthcareDrug Manufacturers - Specialty & Generic

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	Kilitch Drugs (India)	230.40	26.2	806	0.00	2	-13.04	45	4.03	13.2	12.5	2.88	14.5	0.32	71.76	235	28.0
2.	Sun Pharmaceutical Industries	1,758.80	34.9	4,21,995	0.91	2,895	34.65	15,184	18.48	17.9	14.7	5.05	23.4	0.06	55.61	58,220	10.4
3.	Divi's Laboratories	9,144.50	83.0	2,42,758	0.33	902	36.25	3,080	19.15	19.0	16.2	14.48	28.4	0.00	52.00	10,476	11.0
4.	Torrent Pharmaceuticals	4,558.90	72.8	1,73,406	0.83	566	3.28	4,921	54.85	9.1	27.1	18.39	25.0	1.79	63.18	13,980	13.3
5.	Zydus Lifesciences	1,123.00	25.0	1,12,020	0.09	940	-19.74	7,802	24.03	19.0	19.7	4.17	21.7	0.46	75.18	26,720	16.5
6.	Laurus Labs	2,060.10	101.8	1,11,310	0.12	362	123.94	2,026	29.10	19.5	18.2	20.98	19.4	0.48	32.03	6,813	3.8
7.	Cipla	1,325.10	31.8	1,07,051	0.98	789	-35.42	7,077	7.26	14.9	11.8	3.11	17.5	0.02	31.13	27,712	7.2
8.	Dr. Reddy's Laboratories	1,233.00	31.0	1,02,707	0.66	444	-68.72	8,071	-5.56	14.2	12.1	2.68	14.9	0.21	30.14	33,593	11.0
9.	Aurobindo Pharma	1,666.90	26.0	95,910	0.00	1,033	14.29	9,106	8.65	13.5	9.9	2.56	15.6	0.21	54.79	33,385	10.7
10.	Mankind Pharma	2,275.50	46.0	93,988	0.00	574	29.12	4,031	12.89	13.7	12.5	5.76	19.9	0.39	75.39	14,278	17.7
	Median: 48 Co.	1,712.85	31.0	17,493	0.33	682	8.79	5,999	15.68	14.6	13.8	4.10	16.0	0.27	55.20	20,499	13.4

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Consolidated figures in ₹ crore /

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	37	41	32	45	33	47	56	61	43	49	54	90	45
YOY Sales Growth %	9.28%	34.22%	6.08%	-1.45%	-8.49%	15.22%	76.65%	36.61%	28.96%	3.05%	-4.20%	46.35%	4.03%
	30	33	30	38	32	41	47	47	40	44	48	67	42
Material Cost %	47%	49%	53%	55%	55%	52%	58%	47%	59%	54%	57%	49%	53%
Employee Cost %	7%	6%	8%	5%	8%	5%	6%	5%	6%	8%	7%	5%	9%
Other Expenses %	30%	24%	32%	24%	32%	30%	21%	25%	27%	28%	25%	21%	31%
Operating Profit	6	9	2	7	2	6	9	15	3	5	6	22	3
OPM %	17%	21%	7%	16%	5%	13%	16%	24%	8%	10%	11%	25%	7%
Other Income	1	0	3	0	3	5	2	2	3	7	2	0	3
Interest	1	2	2	1	2	0	1	2	2	1	1	1	1
Depreciation	1	1	1	1	1	1	1	1	1	1	1	1	1
Profit before tax	4	7	3	5	2	10	8	14	3	9	6	20	4
	31%	25%	38%	31%	93%	17%	32%	26%	34%	14%	23%	26%	49%
Current tax	2	2	1	1	1	2	3	4	1	2	2	6	2
Deferred tax	-1	-0	-0	0	0	-0	-0	0	-0	-0	-0	-1	0
	3	5	2	4	0	9	6	10	2	8	4	15	2
Minority share	-0	0	-1	0		-0	-0	-0	-1	-0	-0	0	-1
Profit to shareholders	3	5	3	4		9	6	10	3	8	4	15	3
YOY Profit Growth %	76.14%	163.03%	1.96%	26.86%	-96.34%	69.07%	222.39%	177.63%	1,921.89%	-6.64%	-23.14%	45.64%	-13.04%
EPS in Rs	1.08	1.47	0.93	1.12	0.42	2.68	1.86	3.24	0.94	2.49	1.25	4.24	0.83
Raw filing

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	31	32	30	39	33	45	47	56	34	38	45	72	41
YOY Sales Growth %	32.06%	40.77%	4.43%	-9.58%	7.38%	43.63%	56.27%	43.87%	2.10%	-16.62%	-3.96%	27.82%	19.90%
	26	26	26	34	30	40	38	42	31	34	39	52	36
Material Cost %	45%	47%	51%	56%	55%	51%	53%	46%	51%	47%	53%	42%	49%
Employee Cost %	6%	6%	7%	5%	7%	5%	6%	5%	7%	9%	7%	5%	9%
Other Expenses %	32%	28%	29%	25%	28%	31%	24%	25%	31%	35%	28%	26%	31%
Operating Profit	5	6	4	5	3	6	8	14	4	4	6	19	5
OPM %	17%	18%	14%	13%	10%	12%	17%	25%	10%	10%	13%	27%	11%
Other Income	1	1	3	1	3	6	2	2	3	8	2	1	4
Interest	0	0	1	0	0	0	0	1	1	1	1	1	0
Depreciation	0	0	0	0	0	0	0	1	0	1	1	1	1
Profit before tax	6	6	7	5	6	11	10	15	6	10	6	19	7
	25%	28%	16%	31%	27%	16%	28%	24%	20%	13%	21%	28%	27%
Current tax	2	2	1	1	1	2	3	4	1	2	2	6	2
Deferred tax	-1	-0	-0	0	0	-0	-0	0	-0	-0	-0	-1	0
	4	4	5	4	4	9	7	11	5	9	5	14	5
YOY Profit Growth %	38.96%	16.42%	39.94%	-28.98%	-3.22%	108.46%	25.15%	212.31%	18.26%	-1.47%	-28.94%	23.08%	5.39%
EPS in Rs	1.35	1.30	1.74	1.13	1.26	2.75	2.14	3.54	1.49	2.64	1.37	4.08	1.45
Raw filing

Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ Cr	Mar 2017	Mar 2018	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	51	51	53	69	114	140	154	198	235	237
YOY Sales Growth %			4.52%	28.51%	66.71%	22.20%	10.58%	28.47%	18.74%
	46	46	53	63	104	122	130	167	199	201
Material Cost %	51%	51%	55%	54%	57%	54%	51%	53%	54%	53%
Employee Cost %	8%	8%	11%	8%	5%	8%	6%	6%	6%	7%
Other Expenses %	30%	30%	34%	30%	28%	25%	27%	26%	25%	25%
Operating Profit	5	5	0	5	10	18	24	31	37	36
OPM %	10%	10%	0%	8%	9%	13%	16%	16%	16%	15%
Other Income	3	3	4	3	3	3	4	11	11	12
Interest			1	1	1	5	6	5	6	5
Depreciation	2	2	2	2	2	4	3	3	4	4
Profit before tax	6	6	2	5	10	12	19	34	39	39
	16%	16%	48%	26%	35%	31%	30%	28%	24%	25%
Current tax	0	0	1	2	4	4	6	10	11
Deferred tax	1	1	0	-0	-0	-0	-1	-0	-2
	5	5	1	4	6	8	14	25	30	29
Minority share				0	-1	-2	-1	-2	-1	-1
Profit to shareholders			1	4	7	10	15	27	30	30
YOY Profit Growth %			-83.66%	347.34%	64.97%	33.30%	63.90%	83.72%	18.28%
EPS in Rs	1.95	1.95	0.28	1.19	2.37	3.36	4.59	8.30	8.91	8.81
Dividend Payout %					16%

Compounded Sales Growth

5 Years:: 28%
3 Years:: 19%
TTM:: 14%

Compounded Profit Growth

5 Years:: 51%
3 Years:: 53%
TTM:: 9%

Stock Price CAGR

5 Years:: 23%
3 Years:: 21%
1 Year:: 24%

Return on Equity

4 Years:: 11%
Last Year:: 13%

₹ Cr	Mar 2017	Mar 2018	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	50	50	61	70	105	118	132	182	189	195
YOY Sales Growth %			20.43%	15.22%	50.19%	12.00%	11.73%	37.99%	3.85%
	45	45	59	65	94	101	111	151	156	162
Material Cost %	51%	51%	59%	56%	57%	50%	50%	51%	47%	47%
Employee Cost %	8%	8%	9%	7%	6%	6%	6%	6%	7%	7%
Other Expenses %	29%	29%	30%	29%	26%	29%	28%	27%	29%	29%
Operating Profit	6	6	1	5	11	17	20	31	32	34
OPM %	11%	11%	2%	7%	10%	15%	15%	17%	17%	17%
Other Income	3	3	6	4	5	5	6	14	14	14
Interest			1	1	1	1	2	2	2	2
Depreciation	1	1	1	1	1	1	1	2	2	3
Profit before tax	7	7	5	8	14	19	23	41	42	43
	13%	13%	15%	18%	24%	19%	25%	23%	22%	23%
Current tax	0	0	1	2	4	4	6	10	11
Deferred tax	1	1	0	-0	-0	-0	-1	-0	-2
	6	6	4	6	11	16	18	31	32	33
YOY Profit Growth %			-28.06%	38.10%	71.03%	49.29%	11.81%	77.29%	3.99%
EPS in Rs	2.34	2.34	1.45	1.99	3.38	5.05	5.52	9.69	9.57	9.54
Dividend Payout %					11%

Compounded Sales Growth

5 Years:: 22%
3 Years:: 17%
TTM:: 7%

Compounded Profit Growth

5 Years:: 39%
3 Years:: 27%
TTM:: 2%

Stock Price CAGR

5 Years:: 23%
3 Years:: 21%
1 Year:: 24%

Return on Equity

4 Years:: 11%
Last Year:: 13%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	16	16	16	35
Reserves	136	160	186	245
	22	32	49	89
Long term borrowings			28	59
Short term borrowings	22	32	22	30
	46	32	61	89
Trade payables	41	26	54	80
Minority interest	-1	-1	-2	-3
Current liabilities	69	64	84	122
Total Liabilities	220	240	313	458
	47	48	93	189
Gross block	72	76	122	221
Accumulated depreciation	25	27	29	32
Goodwill & intangibles	20	20	19	18
CWIP	4	6	47	140
	169	186	173	129
Inventories	2	6	22	12
Trade receivables	54	63	85	120
Cash & equivalents	20	19	10	16
Current assets	126	146	174	222
Total Assets	220	240	313	458

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	3	-2	18	24
Profit for the year	10	15	27	30
Working capital changes	-15	-24	-10	-12
Direct taxes paid	-4	-7	-8	-11
	8	-8	-40	-100
Fixed assets purchased	-4	-6	-47	-100
Investments purchased		-2	-0	-1
Investments sold	9		5
	-1	9	13	82
Proceeds from borrowings	2	9	18	39
Interest paid	-5	-6	-5	-6
Net Cash Flow	10	-1	-9	6
Free Cash Flow	-1	-8	-29	-76

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	—	6.9%	8.9%	14.1%	12.5%
ROCE	—	11.2%	14.4%	17.3%	13.2%
Operating margin	—	10.3%	13.7%	14.5%	14.5%
Net margin	—	7.5%	9.5%	13.5%	12.8%
Debt / equity	—	0.15	0.18	0.24	0.32
Current ratio	—	1.84	2.27	2.06	1.83
Debtor days	—	143	150	157	186
Inventory days	—	11	25	74	34
Days payable	—	193	116	185	225
Cash conversion cycle	—	-39	59	46	-5
Working capital days	—	151	194	166	156

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 63.77%
FIIs 0.11%
DIIs 0.50%
Public 35.62%

%	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	69.23%	69.23%	69.23%	69.23%	69.23%	69.23%	69.23%	63.77%	63.77%	63.77%	63.77%	63.77%
											0.12%	0.11%
Foreign portfolio investors (Cat. I)											0.09%	0.01%
Foreign portfolio investors (Cat. II)											0.03%	0.09%
												0.50%
Alternative investment funds												0.50%
	30.77%	30.77%	30.77%	30.76%	30.77%	30.77%	30.76%	36.23%	36.23%	36.22%	36.11%	35.62%
Retail (up to ₹2 lakh)	16.81%	16.32%	16.01%	16.02%	16.43%	15.96%	16.15%	18.02%	19.35%	16.58%	17.47%	17.02%
HNIs (above ₹2 lakh)	9.32%	9.06%	9.20%	9.08%	9.31%	9.61%	9.39%	12.20%	11.69%	13.12%	12.17%	12.00%
NRIs	1.02%	1.02%	1.01%	1.05%	1.02%	1.01%	1.07%	1.08%	1.09%	1.13%	1.18%	1.36%
Bodies corporate	0.88%	1.71%	1.95%	2.06%	1.38%	1.72%	1.78%	1.45%	1.20%	1.07%	0.73%	0.71%
IEPF	1.45%	1.45%	1.45%	1.45%	1.45%	1.45%	1.45%	1.32%	1.32%	2.30%	2.29%	2.29%
No. of Shareholders	9,062	9,525	9,620	9,920	10,139	9,749	10,379	10,929	12,043	11,785	12,627	12,319

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

None filed recently.

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Ex-dividend date: 20 Sep 2019
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

Kilitch Drugs (India) Limited (KILITCH.NS) Q2 2026 Earnings: Double-Digit Revenue Growth Offsets Flat Stock Response - Profit Growth Outlookhttps://www.siam.in/ · 1 Oct 2026

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about Kilitch Drugs (India) Limited

What is the share price of Kilitch Drugs (India) Limited today?

Kilitch Drugs (India) Limited (KILITCH) last traded at ₹230.40 on NSE (16 Oct 2026, 3:29 PM IST). Prices may be delayed.

What is the market cap of Kilitch Drugs (India) Limited?

About ₹806 crore at the latest price.

What is the P/E ratio of Kilitch Drugs (India) Limited?

About 26.2 times its earnings over the last 12 months.

Is Kilitch Drugs (India) Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy Kilitch Drugs (India) Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.

Kilitch Drugs (India) Limited share price

Price chart

Quick take

Pros

Cons

AI analysis

About Kilitch Drugs (India) Limited

Peer comparison

Quarterly Results

Profit & Loss

Projection — your assumptions

Related party transactions

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Documents

Announcements

Annual reports

Credit ratings

Concalls & investor meets

Key dates

Trade with our broking desk

Latest news

In the news

From the company (NSE)

Questions about Kilitch Drugs (India) Limited

Have a question about this topic?

Book your free wealth consultation

Request received!

What happens next